Table 2.
Characteristics of the subjects enrolled in the study.
| RNAseq cohort | Validation cohort | |||||
|---|---|---|---|---|---|---|
| PD_R | PD_NR | HC_NR | PD_R | PD_NR | HC_NR | |
| Total subjects enrolled | 15 | 21 | 20 | 10 | 10 | 10 |
| Median age (range), yr | 70 (49–81) | 66 (44–81) | 67 (50–79) | 67 (46–81) | 65 (44–76) | 52 (22–69) |
| Male, % (n) | 73.3% (11) | 80.9% (17) | 20% (4) | 70% (7) | 70% (7) | 50% (5) |
| Caucasian, % (n) | 100% (15) | 85.7% (18) | 80.9% (17) | 90% (9) | 100% (10) | 50% (5) |
| Median years since diagnosis, (range), yr | 3 (0–12) | 6 (0–16) | NA | 5 (1–12) | 11 (1–19) | NA |
| Median MoCAa (range) | 27 (9–30) | 26 (23–30) | NA | 28 (22–30) | 28 (14–30) | NA |
| Median UPDRS part IIIb (range) | 18 (7–37) | 20 (5–30) | NA | 19 (14–25) | 18 (11–52) | NA |
aMoCA collected for n = 32 PD patients in the RNAseq cohort and n = 17 in the validation cohort.
bUPDRS part III was collected during the on-phase for n = 31 PD patients in the RNAseq cohort and =17 in the validation cohort.